Clinical trials: NASH
Nonalcoholic Steatohepatitis, Osteoarthritis
FTIH Study of ECC0509 in Healthy Volunteers
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in…
- Trial name
- NCT05012423
- Testing
- ECC0509
- Where
- Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Eccogene
Nonalcoholic Steatohepatitis
First-in-Human Study of SRT-015 in Healthy Subjects.
This is phase 1 first-in-human trial evaluating SRT-015 to assess safety, tolerability and pharmacokinetics. This study will be conducted in 3 parts - SAD, MAD and Food Effect with target of 96 healthy volunteers.
- Trial name
- NCT04887038
- Testing
- SRT-015
- Where
- Australia
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Syneos Health
Fat; Liver, NAFLD
The Effect of a High-fat vs. High-sugar Diet on Liver Fat Accumulation and Metabolism
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world. It is currently unclear why fat starts to accumulate in the liver, although both the amount and type of food consumed have been…
- Trial name
- NCT03145350
- Testing
- High-fat, low-carbohydrate, Low-fat, high-carbohydrate
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
Biomarkers of Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis Following Bariatric Surgery
The purpose of this study is to evaluate imaging and other biomarkers of non-alcoholic fatty liver disease before and after bariatric surgery.
- Trial name
- BARI (NCT03294850)
- Testing
- Bariatric surgery, HepQuant SHUNT Dual Cholate Liver Diagnostic Kit
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Non-alcoholic Fatty Liver Disease
Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)
In this multicentric, double-blind, randomized,placebo-controlled study, the investigators hypothesized that rifaximin might act on Gram-negative bacteria and intestinal bacterial overgrowth(IBO) thereby inhibiting…
- Trial name
- NCT02884037
- Testing
- Rifaximin group 1
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Chronic Liver Disease, Liver Fibrosis
Comparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouch
This study is aimed to compare the results and operating characteristics of liver stiffness measurement with the use of Fibroscan (EchoSens, France) and iLivTouch (Wuxi Hisky Medical Technologies Co., China) in patients with…
- Conditions
- Chronic Liver Disease, Liver Fibrosis, Liver Steatoses
- Trial name
- OGIG-01-22-LF (NCT05224037)
- Testing
- iLivTouch
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Federal State Budgetary Scientific Institution
NAFLD
C1q/TNF-related Proteins in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is characterized by an accumulation of fat in the liver, which is one of the most common forms of chronic liver disease in developed countries.
- Trial name
- NCT02083159
- Where
- South Korea
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Korea University
Nonalcoholic Fatty Liver Disease, Obesity
High Fructose Corn Syrup
The purpose of this research study is to learn more about how high fructose corn syrup, a sugar used to sweeten drinks and foods, affects metabolism in obese persons with and without nonalcoholic fatty liver disease.
- Trial name
- Fructose (NCT02018237)
- Testing
- High fructose corn syrup diet, Standard diet (low in high fructose corn syrup)
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Pre Diabetes, Impaired Glucose Tolerance
Effect of F. Prausnitzii on Glycemic Control
The microbiota is associated with a wide spectrum of diseases including diabetes and non-alcoholic fatty liver disease. In this study we will investigate if the bacteria F.
- Conditions
- Pre Diabetes, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04938843
- Testing
- F. prausnitzii and D. piger
- Where
- Sweden
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- MetaboGen AB
Non-Alcoholic Fatty Liver Disease, Immune Response
The Role of Immune Semaphorins in NAFLD
To goal is to identify semaphorins that are associated with NAFLD and to investigate their relationship with variable degrees of steatosis and fibrosis.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Immune Response, Biomarkers, Liver Fibrosis
- Trial name
- SepsisFAT (NCT04573543)
- Testing
- Evaluation of the degree of fibrosis and steatosis, Screening for the components of metabolic syndrome, Measurement of serum semaphorin concentrations
- Where
- Croatia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University Hospital for Infectious Diseases, Croatia
Liver Diseases, Humans
Liver Disease and Other Systemic Diseases
Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing…
- Conditions
- Liver Diseases, Humans, Progression, Carcinogenesis
- Trial name
- NCT04525833
- Where
- Taiwan
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Glucagon Resistance in Patients With NAFLD
The investigators propose that the sensitivity to glucagon in hepatic lipid metabolism is impaired in subjects with non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Glucose Metabolism Disorders
- Trial name
- NCT04042142
- Testing
- glucagon
- Where
- Denmark
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Overweight, Obese
The Effect of Protein-enriched Diet on Body Composition and Appetite
Obesity is a major problem worldwide and current dietary interventions are not proving to be enough to cease the increase in levels of obesity and its detrimental side effects, such as nonalcoholic fatty liver disease (NAFLD).
- Conditions
- Overweight, Obese, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease
- Trial name
- ProteinRich (NCT01634048)
- Testing
- High Protein, low calorie meal replacement
- Where
- United Kingdom
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Non-alcoholic Fatty Liver Disease (NAFLD)
The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients
In this first pilot study, we will examine the effects of acetaminophen dosing in adult patients with NAFLD in comparison to the effects in a healthy control group.
- Trial name
- NCT02194894
- Testing
- Acetaminophen
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Southern California
Insulin Resistance, Hyperinsulinemia
Effect of Alpelisib in Healthy Volunteers
The goal of this clinical trial is to test a single dose of the phosphoinositide-3-kinase (PI3K) inhibitor alpelisib versus placebo in healthy volunteers.
- Conditions
- Insulin Resistance, Hyperinsulinemia, Dyslipidemias
- Trial name
- NCT05733455
- Testing
- Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Columbia University
Liver Biomarkers, Lipid Profile
Improvement in Hepatic Function Through Sumac (Rhus Coriaria L.) Supplement Along With a Calorie-restricted Diet for the Management of Grade-I Obese Non-alcoholic Fatty Liver Disease Patients
This randomized controlled trial aims to evaluate the effects of Rhus coriaria L. (Sumac) supplementation combined with a calorie-restricted diet on hepatic function and metabolic health in grade-I obese patients with…
- Conditions
- Liver Biomarkers, Lipid Profile, Glucose, Insulin
- Trial name
- NCT07768657
- Testing
- T1 SUMAC SUPPLEMENT, T2 SUMAC SUPPLEMENT
- Where
- Pakistan
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University of Lahore
Nonalcoholic Fatty Liver Disease
A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
This is a 3 part, randomized, double blind, placebo controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending subcutaneous (SC) doses of CB4211 in…
- Trial name
- NCT03998514
- Testing
- CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- CohBar, Inc.
Hepatic Impairment, Healthy Volunteers
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
- Trial name
- NCT04091061
- Testing
- PF-06865571 100 mg
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes
Weight Gain After Smoking Cessation and NAFLD
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common chronic liver disease. Considering that there are no approved pharmacological treatments, lifestyle modification is necessary and challenging to reduce…
- Trial name
- NCT05550688
- Where
- China
- Volunteers
- 12,941 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital